diff --git a/Mapping to LSRs/Mental Health Ontology mapping to LSRs.csv b/Mapping to LSRs/Mental Health Ontology mapping to LSRs.csv index e47e5d7..7392630 100644 --- a/Mapping to LSRs/Mental Health Ontology mapping to LSRs.csv +++ b/Mapping to LSRs/Mental Health Ontology mapping to LSRs.csv @@ -1,7 +1,7 @@ Extraction sheet name,Data file (doi),LSR no.,Extraction sheet dimension,Variable to extract,Understandable label for database,Class ID,Class label,Class definition,Parent class,Ontology spreadsheet,Organised under,COMBO or not?,COMBO LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Outcome,AE,Adverse event,GMHO:0000047,adverse event following an intervention,A pathological bodily process that occurs after the intervention delivery starts.,pathological bodily process,Intervention outcomes and spillover effects,,, LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Outcome,AE,Adverse event,GMHO:0000204,measurement datum at followup,Measurement datum that was recorded as followup data in a study.,measurement datum,Intervention outcomes and spillover effects,,, -LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Population,anhedonia_baseline_direction,Baseline anhedonia scale directionality,GMHO:0000201,anhedonia scale,A measurement scale that is used to measure anhedonia symptom severity.,measurement scale,Intervention population,,, +LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Population,anhedonia_baseline_direction,Baseline anhedonia scale directionality,GMHO:0000201,anhedonia scale,A measurement scale that is used to measure anhedonia symptom severity.,measurement scale,Intervention population,"GMHO:0000131,GMHO:0000209",COMBO,"GMHO:0000201,GMHO:0000212" LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Population,anhedonia_baseline_scale,Baseline anhedonia scale,GMHO:0000201,anhedonia scale,A measurement scale that is used to measure anhedonia symptom severity.,measurement scale,Intervention population,,, LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Outcomes,anhedonia_followup_direction,Followup anhedonia scale directionality,GMHO:0000201,anhedonia scale,A measurement scale that is used to measure anhedonia symptom severity.,measurement scale,Intervention outcomes and spillover effects,,, LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Outcomes,anhedonia_followup_scale,Followup anhedonia scale,GMHO:0000201,anhedonia scale,A measurement scale that is used to measure anhedonia symptom severity.,measurement scale,Intervention outcomes and spillover effects,,, @@ -54,8 +54,8 @@ LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Intervention,treatment_de LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Intervention,tx_duration,Intervention duration,GMHO:0000005,intervention duration,A temporal interval between the start and end of an intervention.,one-dimensional temporal region,Intervention content and delivery,,, LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Intervention,dose_delivered_max,Maximum drug dose delivered,STATO:0000151,maximum value,A data item which denotes the largest value found in a dataset or resulting from a calculation.,statistic,Intervention content and delivery,,, LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Intervention,dose_planned_max,Maximum planned drug dose,STATO:0000151,maximum value,A data item which denotes the largest value found in a dataset or resulting from a calculation.,statistic,Intervention content and delivery,,, -LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Population,age_mean,Mean age,BCIO:015416,mean human age population statistic,The mean of human age in a population.,human age population statistic,Intervention population,,, -LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Population,anhedonia_baseline_mean,Mean baseline anhedonia,GMHO:0000209,measurement datum at baseline,Measurement datum that was recorded as baseline data in a study.,measurement datum,Intervention population,,, +LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Population,age_mean,Mean age,BCIO:015416,mean human age population statistic,The mean of human age in a population.,human age population statistic,Intervention population,Population,No Combo, +LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Population,anhedonia_baseline_mean,Mean baseline anhedonia,GMHO:0000209,measurement datum at baseline,Measurement datum that was recorded as baseline data in a study.,measurement datum,Intervention population,Population,No Combo, LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Population,anhedonia_baseline_n,Number of participants for whom baseline anhedonia was measured,GMHO:0000209,measurement datum at baseline,Measurement datum that was recorded as baseline data in a study.,measurement datum,Intervention population,,, LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Population,anhedonia_baseline_sd,Standard deviation of baseline anhedonia,GMHO:0000209,measurement datum at baseline,Measurement datum that was recorded as baseline data in a study.,measurement datum,Intervention population,,, LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Population,anxiety_baseline_mean,Mean baseline anxiety,GMHO:0000209,measurement datum at baseline,Measurement datum that was recorded as baseline data in a study.,measurement datum,Intervention population,,, @@ -77,7 +77,7 @@ LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Outcomes,reward_followup_ LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Outcomes,reward_followup_n,Number of participants for whom followup reward sensitivity was measured,GMHO:0000204,measurement datum at followup,Measurement datum that was recorded as followup data in a study.,measurement datum,Intervention outcomes and spillover effects,,, LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Outcomes,reward_followup_sd,Standard deviation of followup reward sensitivity,GMHO:0000204,measurement datum at followup,Measurement datum that was recorded as followup data in a study.,measurement datum,Intervention outcomes and spillover effects,,, LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Outcomes,reward_followup_type,Followup reward sensitivity data type,GMHO:0000204,measurement datum at followup,Measurement datum that was recorded as followup data in a study.,measurement datum,Intervention outcomes and spillover effects,,, -LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Population,anhedonia_baseline_direction,Baseline anhedonia scale directionality,GMHO:0000212,measurement scale at baseline,A measurement scale used to measure baseline data in a study.,measurement scale,Intervention population,,, +LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Population,anhedonia_baseline_direction,Baseline anhedonia scale directionality,GMHO:0000212,measurement scale at baseline,A measurement scale used to measure baseline data in a study.,measurement scale,Intervention population,"GMHO:0000131,GMHO:0000209",COMBO,"GMHO:0000201,GMHO:0000212" LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Population,anhedonia_baseline_scale,Baseline anhedonia scale,GMHO:0000212,measurement scale at baseline,A measurement scale used to measure baseline data in a study.,measurement scale,Intervention population,,, LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Population,anxiety_baseline_direction,Baseline anxiety scale directionality,GMHO:0000212,measurement scale at baseline,A measurement scale used to measure baseline data in a study.,measurement scale,Intervention population,,, LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Population,reward_baseline_direction,Baseline reward sensitivity scale directionality,GMHO:0000212,measurement scale at baseline,A measurement scale used to measure baseline data in a study.,measurement scale,Intervention population,,, @@ -115,7 +115,7 @@ LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Population,reward_baselin LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Population,reward_baseline_scale,Baseline reward sensitivity scale,GMHO:0000207,reward sensitivity scale,A measurement scale that is used to measure reward sensitivity.,measurement scale,Intervention population,,, LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Outcomes,reward_followup_direction,Followup reward sensitivity scale directionality,GMHO:0000207,reward sensitivity scale,A measurement scale that is used to measure reward sensitivity.,measurement scale,Intervention outcomes and spillover effects,,, LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Outcomes,reward_followup_scale,Followup reward sensitivity scale,GMHO:0000207,reward sensitivity scale,A measurement scale that is used to measure reward sensitivity.,measurement scale,Intervention outcomes and spillover effects,,, -LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Population,anhedonia_baseline_direction,Baseline anhedonia scale directionality,GMHO:0000208,scale directionality,An information content entity about the orientation of a measurement's scoring system in which higher numerical levels can indicate higher or lower levels of a construct. ,information content entity,Intervention population,,, +LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Population,anhedonia_baseline_direction,Baseline anhedonia scale directionality,GMHO:0000208,scale directionality,An information content entity about the orientation of a measurement's scoring system in which higher numerical levels can indicate higher or lower levels of a construct. ,information content entity,Intervention population,"GMHO:0000201,GMHO:0000212",No Combo, LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Outcomes,anhedonia_followup_direction,Followup anhedonia scale directionality,GMHO:0000208,scale directionality,An information content entity about the orientation of a measurement's scoring system in which higher numerical levels can indicate higher or lower levels of a construct. ,information content entity,Intervention outcomes and spillover effects,,, LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Population,anxiety_baseline_direction,Baseline anxiety scale directionality,GMHO:0000208,scale directionality,An information content entity about the orientation of a measurement's scoring system in which higher numerical levels can indicate higher or lower levels of a construct. ,information content entity,Intervention population,,, LSR1_anhedonia_H/data/human/df_amended_20240430.csv,,1,Outcomes,anxiety_followup_direction,Followup anxiety scale directionality,GMHO:0000208,scale directionality,An information content entity about the orientation of a measurement's scoring system in which higher numerical levels can indicate higher or lower levels of a construct. ,information content entity,Intervention outcomes and spillover effects,,, @@ -140,8 +140,8 @@ LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.108 LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,state,Severity of condition,GMHO:0000087,symptom severity,A data item that is about the location on the dimension of a symptom.,data item,Intervention population,,, LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,sample_n,Number of intervention participants,BCIO:015095,intervention population,A human population who are exposed to an intervention.,human population,Intervention population,,, LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,randomized_n,Number of intervention participants randomly acllocated to an arm,GMHO:0000154,number of randomised intervention participants,Number of intervention participants who were randomly allocated to study arms within an intervention.,number of intervention participants,Intervention population,,, -LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,age_mean,Mean age,BCIO:015416,mean human age population statistic,The mean of human age in a population.,human age population statistic,Intervention population,,, -LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,female_n,Number of female participants,GMHO:0000213,number of female biological sex,The number of female biological sex in a population.,female biological sex population statistic,Intervention population,,, +LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,age_mean,Mean age,BCIO:015416,mean human age population statistic,The mean of human age in a population.,human age population statistic,Intervention population,Population,No Combo, +LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,female_n,Number of female participants,GMHO:0000213,number of female biological sex,The number of female biological sex in a population.,female biological sex population statistic,Intervention population,Population,No Combo, LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,duration_weeks,Intervention duration (weeks),GMHO:0000005,intervention duration,A temporal interval between the start and end of an intervention.,one-dimensional temporal region,Intervention content and delivery,,, LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,response_e,Number of participants who had a response to treatments,GMHO:0000076,positive intervention outcome,An intervention outcome that is positively influenced by the intervention. ,intervention outcome,Intervention outcomes and spillover effects,,, LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,response_e,Number of participants who had a response to treatments,GMHO:0000214,number of participants with specific outcome,Number of intervention participants for whom an outcome has been identified within a study.,number of intervention participants,Intervention outcomes and spillover effects,,, @@ -302,12 +302,12 @@ LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.108 LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,prolactin_sd,Standard deviation of followup prolactin,GMHO:0000204,measurement datum at followup,Measurement datum that was recorded as followup data in a study.,measurement datum,Intervention outcomes and spillover effects,,, LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,prolactin_change_endpoint,Information available about changes in prolactin,GMHO:0000203,information on available followup data,An information content entity about the followup data available for a study.,information content entity,Intervention outcomes and spillover effects,,, LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,prolactin_change_endpoint,Information available about changes in prolactin,GMHO:0000042,adverse change in prolactin measurement,An adverse change in a bodily measurement parameter relating to prolactin measurement.,adverse change in a bodily measurement parameter,Intervention outcomes and spillover effects,,, -LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,adverse_event_e,Number of participants with adverse events following intervention,GMHO:0000047,adverse event following an intervention,A pathological bodily process that occurs after the intervention delivery starts.,pathological bodily process,Intervention outcomes and spillover effects,,, -LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,adverse_event_e,Number of participants with adverse events following intervention,GMHO:0000214,number of participants with specific outcome,Number of intervention participants for whom an outcome has been identified within a study.,number of intervention participants,Intervention outcomes and spillover effects,,, -LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,adverse_event_e,Number of participants with adverse events following intervention,GMHO:0000204,measurement datum at followup,Measurement datum that was recorded as followup data in a study.,measurement datum,Intervention outcomes and spillover effects,,, -LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,adverse_event_n,Number of participants with measurement for adverse events following intervention,GMHO:0000047,adverse event following an intervention,A pathological bodily process that occurs after the intervention delivery starts.,pathological bodily process,Intervention outcomes and spillover effects,,, -LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,adverse_event_n,Number of participants with measurement for adverse events following intervention,GMHO:0000206,number of participants with measurement,Number of intervention participants for whom a measurement was made.,number of intervention participants,Intervention outcomes and spillover effects,,, -LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,adverse_event_n,Number of participants with measurement for adverse events following intervention,GMHO:0000204,measurement datum at followup,Measurement datum that was recorded as followup data in a study.,measurement datum,Intervention outcomes and spillover effects,,, +LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,adverse_event_e,Number of participants with adverse events following intervention,GMHO:0000047,adverse event following an intervention,A pathological bodily process that occurs after the intervention delivery starts.,pathological bodily process,Intervention outcomes and spillover effects,Outcome,COMBO,"GMHO:0000047,GMHO:0000204" +LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,adverse_event_e,Number of participants with adverse events following intervention,GMHO:0000214,number of participants with specific outcome,Number of intervention participants for whom an outcome has been identified within a study.,number of intervention participants,Intervention outcomes and spillover effects,"GMHO:0000047,GMHO:0000204",No Combo, +LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,adverse_event_e,Number of participants with adverse events following intervention,GMHO:0000204,measurement datum at followup,Measurement datum that was recorded as followup data in a study.,measurement datum,Intervention outcomes and spillover effects,Outcome,COMBO,"GMHO:0000047,GMHO:0000204" +LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,adverse_event_n,Number of participants with measurement for adverse events following intervention,GMHO:0000047,adverse event following an intervention,A pathological bodily process that occurs after the intervention delivery starts.,pathological bodily process,Intervention outcomes and spillover effects,Outcome,COMBO,"GMHO:0000047,GMHO:0000204" +LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,adverse_event_n,Number of participants with measurement for adverse events following intervention,GMHO:0000206,number of participants with measurement,Number of intervention participants for whom a measurement was made.,number of intervention participants,Intervention outcomes and spillover effects,"GMHO:0000047,GMHO:0000204",No Combo, +LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,adverse_event_n,Number of participants with measurement for adverse events following intervention,GMHO:0000204,measurement datum at followup,Measurement datum that was recorded as followup data in a study.,measurement datum,Intervention outcomes and spillover effects,Outcome,COMBO,"GMHO:0000047,GMHO:0000204" LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,anticholinergic_symptom_e,Number of participants with anticholinergic symptom following intervention,GMHO:0000221,anticholinergic symptom following intervention,An adverse event following an intervention that involves symptoms associated with anticholinergic drugs.,adverse event following an intervention,Intervention outcomes and spillover effects,,, LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,anticholinergic_symptom_e,Number of participants with anticholinergic symptom following intervention,GMHO:0000214,number of participants with specific outcome,Number of intervention participants for whom an outcome has been identified within a study.,number of intervention participants,Intervention outcomes and spillover effects,,, LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,anticholinergic_symptom_e,Number of participants with anticholinergic symptom following intervention,GMHO:0000204,measurement datum at followup,Measurement datum that was recorded as followup data in a study.,measurement datum,Intervention outcomes and spillover effects,,, @@ -356,12 +356,12 @@ LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.108 LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,qtc_prolongation_n,Number of participants with measurement for QTc prolongation following intervention,CMO:0000269,QTc interval,QT interval corrected for heart rate calculated by the QT interval divided by the square root of the interval from one QRS complex to the onset of the next QRS complex measured in seconds.,heart electrical conduction measurement,Intervention outcomes and spillover effects,,, LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,qtc_prolongation_n,Number of participants with measurement for QTc prolongation following intervention,GMHO:0000206,number of participants with measurement,Number of intervention participants for whom a measurement was made.,number of intervention participants,Intervention outcomes and spillover effects,,, LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,qtc_prolongation_n,Number of participants with measurement for QTc prolongation following intervention,GMHO:0000204,measurement datum at followup,Measurement datum that was recorded as followup data in a study.,measurement datum,Intervention outcomes and spillover effects,,, -LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,agitation_e,Number of participants with agitation following intervention,GMHO:0000233,agitation following intervention,An adverse event following an intervention that involves experiencing agitation.,adverse event following an intervention,Intervention outcomes and spillover effects,,, -LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,agitation_e,Number of participants with agitation following intervention,GMHO:0000214,number of participants with specific outcome,Number of intervention participants for whom an outcome has been identified within a study.,number of intervention participants,Intervention outcomes and spillover effects,,, -LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,agitation_e,Number of participants with agitation following intervention,GMHO:0000204,measurement datum at followup,Measurement datum that was recorded as followup data in a study.,measurement datum,Intervention outcomes and spillover effects,,, -LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,agitation_n,Number of participants with measurement for agitation following intervention,GMHO:0000233,agitation following intervention,An adverse event following an intervention that involves experiencing agitation.,adverse event following an intervention,Intervention outcomes and spillover effects,,, -LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,agitation_n,Number of participants with measurement for agitation following intervention,GMHO:0000206,number of participants with measurement,Number of intervention participants for whom a measurement was made.,number of intervention participants,Intervention outcomes and spillover effects,,, -LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,agitation_n,Number of participants with measurement for agitation following intervention,GMHO:0000204,measurement datum at followup,Measurement datum that was recorded as followup data in a study.,measurement datum,Intervention outcomes and spillover effects,,, +LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,agitation_e,Number of participants with agitation following intervention,GMHO:0000233,agitation following intervention,An adverse event following an intervention that involves experiencing agitation.,adverse event following an intervention,Intervention outcomes and spillover effects,"GMHO:0000047,GMHO:0000204",COMBO,"GMHO:0000233,GMHO:0000204" +LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,agitation_e,Number of participants with agitation following intervention,GMHO:0000214,number of participants with specific outcome,Number of intervention participants for whom an outcome has been identified within a study.,number of intervention participants,Intervention outcomes and spillover effects,"GMHO:0000233,GMHO:0000204",No Combo, +LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,agitation_e,Number of participants with agitation following intervention,GMHO:0000204,measurement datum at followup,Measurement datum that was recorded as followup data in a study.,measurement datum,Intervention outcomes and spillover effects,"GMHO:0000047,GMHO:0000204",COMBO,"GMHO:0000233,GMHO:0000204" +LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,agitation_n,Number of participants with measurement for agitation following intervention,GMHO:0000233,agitation following intervention,An adverse event following an intervention that involves experiencing agitation.,adverse event following an intervention,Intervention outcomes and spillover effects,"GMHO:0000047,GMHO:0000204",COMBO,"GMHO:0000233,GMHO:0000204" +LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,agitation_n,Number of participants with measurement for agitation following intervention,GMHO:0000206,number of participants with measurement,Number of intervention participants for whom a measurement was made.,number of intervention participants,Intervention outcomes and spillover effects,"GMHO:0000233,GMHO:0000204",No Combo, +LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,agitation_n,Number of participants with measurement for agitation following intervention,GMHO:0000204,measurement datum at followup,Measurement datum that was recorded as followup data in a study.,measurement datum,Intervention outcomes and spillover effects,"GMHO:0000047,GMHO:0000204",COMBO,"GMHO:0000233,GMHO:0000204" LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,hypotension_e,Number of participants with hypotension following intervention,GMHO:0000235,hypotension following intervention,An adverse event following an intervention that involves experiencing low blood pressure.,adverse event following an intervention,Intervention outcomes and spillover effects,,, LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,hypotension_e,Number of participants with hypotension following intervention,GMHO:0000214,number of participants with specific outcome,Number of intervention participants for whom an outcome has been identified within a study.,number of intervention participants,Intervention outcomes and spillover effects,,, LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,hypotension_e,Number of participants with hypotension following intervention,GMHO:0000204,measurement datum at followup,Measurement datum that was recorded as followup data in a study.,measurement datum,Intervention outcomes and spillover effects,,, @@ -374,12 +374,12 @@ LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.108 LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,insomnia_n,Number of participants with measurement for insomnia following intervention,GMHO:0000182,insomnia following intervention,An adverse event following an intervention in which there is an inability to fall asleep or to stay asleep as long as desired.,adverse event following an intervention,Intervention outcomes and spillover effects,,, LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,insomnia_n,Number of participants with measurement for insomnia following intervention,GMHO:0000206,number of participants with measurement,Number of intervention participants for whom a measurement was made.,number of intervention participants,Intervention outcomes and spillover effects,,, LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,insomnia_n,Number of participants with measurement for insomnia following intervention,GMHO:0000204,measurement datum at followup,Measurement datum that was recorded as followup data in a study.,measurement datum,Intervention outcomes and spillover effects,,, -LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,akathisia_e,Number of participants with akathisia following intervention,GMHO:0000051,akathisia following pharmacological intervention,"A drug-induced movement disorder following intervention that involves feeling restlessness, increased urges to move and reduced capability to suppress such urges.",drug-induced movement disorder following intervention,Intervention outcomes and spillover effects,,, -LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,akathisia_e,Number of participants with akathisia following intervention,GMHO:0000214,number of participants with specific outcome,Number of intervention participants for whom an outcome has been identified within a study.,number of intervention participants,Intervention outcomes and spillover effects,,, -LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,akathisia_e,Number of participants with akathisia following intervention,GMHO:0000204,measurement datum at followup,Measurement datum that was recorded as followup data in a study.,measurement datum,Intervention outcomes and spillover effects,,, -LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,akathisia_n,Number of participants with measurement for akathisia following intervention,GMHO:0000051,akathisia following pharmacological intervention,"A drug-induced movement disorder following intervention that involves feeling restlessness, increased urges to move and reduced capability to suppress such urges.",drug-induced movement disorder following intervention,Intervention outcomes and spillover effects,,, -LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,akathisia_n,Number of participants with measurement for akathisia following intervention,GMHO:0000206,number of participants with measurement,Number of intervention participants for whom a measurement was made.,number of intervention participants,Intervention outcomes and spillover effects,,, -LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,akathisia_n,Number of participants with measurement for akathisia following intervention,GMHO:0000204,measurement datum at followup,Measurement datum that was recorded as followup data in a study.,measurement datum,Intervention outcomes and spillover effects,,, +LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,akathisia_e,Number of participants with akathisia following intervention,GMHO:0000051,akathisia following pharmacological intervention,"A drug-induced movement disorder following intervention that involves feeling restlessness, increased urges to move and reduced capability to suppress such urges.",drug-induced movement disorder following intervention,Intervention outcomes and spillover effects,GMHO:0000063,COMBO,"GMHO:0000051,GMHO:0000204" +LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,akathisia_e,Number of participants with akathisia following intervention,GMHO:0000214,number of participants with specific outcome,Number of intervention participants for whom an outcome has been identified within a study.,number of intervention participants,Intervention outcomes and spillover effects,"GMHO:0000051,GMHO:0000204",No Combo, +LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,akathisia_e,Number of participants with akathisia following intervention,GMHO:0000204,measurement datum at followup,Measurement datum that was recorded as followup data in a study.,measurement datum,Intervention outcomes and spillover effects,GMHO:0000063,COMBO,"GMHO:0000051,GMHO:0000204" +LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,akathisia_n,Number of participants with measurement for akathisia following intervention,GMHO:0000051,akathisia following pharmacological intervention,"A drug-induced movement disorder following intervention that involves feeling restlessness, increased urges to move and reduced capability to suppress such urges.",drug-induced movement disorder following intervention,Intervention outcomes and spillover effects,GMHO:0000063,COMBO,"GMHO:0000051,GMHO:0000204" +LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,akathisia_n,Number of participants with measurement for akathisia following intervention,GMHO:0000206,number of participants with measurement,Number of intervention participants for whom a measurement was made.,number of intervention participants,Intervention outcomes and spillover effects,"GMHO:0000051,GMHO:0000204",No Combo, +LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,akathisia_n,Number of participants with measurement for akathisia following intervention,GMHO:0000204,measurement datum at followup,Measurement datum that was recorded as followup data in a study.,measurement datum,Intervention outcomes and spillover effects,GMHO:0000063,COMBO,"GMHO:0000051,GMHO:0000204" LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,eps_symptoms_e,Number of participants with extrapyrimidal symptoms following intervention,GMHO:0000063,drug-induced movement disorder following intervention,An adverse event following a pharmacological intervention that involves reduced abilities to control movements.,adverse event following an intervention,Intervention outcomes and spillover effects,,, LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,eps_symptoms_e,Number of participants with extrapyrimidal symptoms following intervention,GMHO:0000214,number of participants with specific outcome,Number of intervention participants for whom an outcome has been identified within a study.,number of intervention participants,Intervention outcomes and spillover effects,,, LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.10890206,3,,eps_symptoms_e,Number of participants with extrapyrimidal symptoms following intervention,GMHO:0000204,measurement datum at followup,Measurement datum that was recorded as followup data in a study.,measurement datum,Intervention outcomes and spillover effects,,, @@ -565,8 +565,8 @@ LSR3_taar1_H/data/data_2024-01-22_LSR3_H.xlsx,https://doi.org/10.5281/zenodo.108 ,,2,,Therapy,Type of psychological treatment,GMHO:0000239,psychological treatment,Mental health intervention content that uses communication or recommended tasks to assess and improve a person’s adaptive mental or behavioural functioning.,mental health intervention content,Intervention content and delivery,,, ,,2,,TAU,Treatment as usual,GMHO:0000128,treatment as usual control arm,A control arm designation where the same content and delivery is already provided as standard practice.,control arm,Intervention content and delivery,,, ,,2,,year,Year of publication,GMHO:0000120,publication year textual entity,A textual entity documenting the year in which some study was published.,textual entity,Research methods,,, -,,2,,AGEm,Mean age,BCIO:015416,mean human age population statistic,The mean of human age in a population.,human age population statistic,Intervention population,,, -,,2,,tg1specEX2,Type of exercise carried out in the intervention arm,GMHO:0000123,intervention arm,A study arm that is subject to evaluation in an intervention evaluation study.,study arm,Intervention content and delivery,,, +,,2,,AGEm,Mean age,BCIO:015416,mean human age population statistic,The mean of human age in a population.,human age population statistic,Intervention population,Population,No Combo, +,,2,,tg1specEX2,Type of exercise carried out in the intervention arm,GMHO:0000123,intervention arm,A study arm that is subject to evaluation in an intervention evaluation study.,study arm,Intervention content and delivery,Population,No Combo, ,,2,,Intervention,Intervention details,GMHO:0000241,mental health intervention content,An intervention content that is part of a mental health intervention.,intervention content,Intervention content and delivery,,, ,,2,,Intervention,Intervention details,GMHO:0000123,intervention arm,A study arm that is subject to evaluation in an intervention evaluation study.,study arm,Intervention content and delivery,,, ,,2,,Comparison,Control group details,GMHO:0000122,control arm,A study arm designation as a comparator to some intervention arm.,study arm,Intervention content and delivery,,,